277 related articles for article (PubMed ID: 16966563)
1. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Deleu D; Jacob P; Chand P; Sarre S; Colwell A
Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
3. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
5. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease.
Nyholm D; Lennernäs H; Johansson A; Estrada M; Aquilonius SM
Clin Neuropharmacol; 2010 Jul; 33(4):181-5. PubMed ID: 20661024
[TBL] [Abstract][Full Text] [Related]
7. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of levodopa.
Nutt JG
Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
[TBL] [Abstract][Full Text] [Related]
9. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
Okereke CS
J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
[TBL] [Abstract][Full Text] [Related]
10. Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
Baas H; Harder S; Demisch L; Bürklin F; Stecker K; Fischer PA
J Neural Transm Suppl; 1995; 46():367-79. PubMed ID: 8821072
[TBL] [Abstract][Full Text] [Related]
11. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252
[TBL] [Abstract][Full Text] [Related]
12. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
Frey KA
Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
[No Abstract] [Full Text] [Related]
13. The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease.
Lopane G; Contin M; Scaglione C; Albani F; Baruzzi A; Martinelli P
Clin Neuropharmacol; 2010; 33(5):254-6. PubMed ID: 20852413
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
[TBL] [Abstract][Full Text] [Related]
16. Levodopa and executive performance in Parkinson's disease: a randomized study.
Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973
[TBL] [Abstract][Full Text] [Related]
19. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
[TBL] [Abstract][Full Text] [Related]
20. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
Nomoto M; Nishikawa N; Nagai M; Yabe H; Nakatsuka A; Moritoyo H; Moritoyo T; Kubo M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S21-4. PubMed ID: 19131037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
